Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C14H22N6O5.ClH |
| Molecular Weight | 390.823 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.CC(C)[C@H](N)C(=O)OC[C@H](CO)OCN1C=NC2=C1N=C(N)NC2=O
InChI
InChIKey=ZORWARFPXPVJLW-OZZZDHQUSA-N
InChI=1S/C14H22N6O5.ClH/c1-7(2)9(15)13(23)24-4-8(3-21)25-6-20-5-17-10-11(20)18-14(16)19-12(10)22;/h5,7-9,21H,3-4,6,15H2,1-2H3,(H3,16,18,19,22);1H/t8-,9-;/m0./s1
| Molecular Formula | ClH |
| Molecular Weight | 36.461 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | C14H22N6O5 |
| Molecular Weight | 354.3617 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Originator
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| High dosage of oral valaciclovir as an alternative treatment of varicella zoster acute retinal necrosis syndrome. | 2006-02 |
|
| Management of cytomegalovirus infection in lung transplant recipients: evidence-based recommendations. | 2005-07-27 |
|
| Cytomegalovirus colitis mimicking ischemic colitis in an immunocompetent host. | 2005-07-20 |
|
| Initial experience with oral valganciclovir for pre-emptive cytomegalovirus therapy after lung transplantation. | 2005-07 |
|
| Treatment of cytomegalovirus infection or disease in solid organ transplant recipients with valganciclovir. | 2005-07 |
|
| Antiviral medications to prevent cytomegalovirus disease and early death in recipients of solid-organ transplants: a systematic review of randomised controlled trials. | 2005-06-21 |
|
| Pharmacodynamics of oral ganciclovir and valganciclovir in solid organ transplant recipients. | 2005-06-15 |
|
| A trial of valganciclovir prophylaxis for cytomegalovirus prevention in lung transplant recipients. | 2005-06 |
|
| Clinical utility of cytomegalovirus (CMV) serology testing in high-risk CMV D+/R- transplant recipients. | 2005-05 |
|
| A novel nucleoside prodrug-activating enzyme: substrate specificity of biphenyl hydrolase-like protein. | 2005-04-19 |
|
| Pharmacokinetics of antiviral agents for the treatment of cytomegalovirus infection. | 2005-04-15 |
|
| Cytomegalovirus retinitis in an immunocompetent patient. | 2005-04 |
|
| Cytomegalovirus prophylaxis with valganciclovir in African-American renal allograft recipients based on donor/recipient serostatus. | 2005-04 |
|
| Pilot study of rapid steroid elimination with alemtuzumab induction therapy in kidney and pancreas transplantation. | 2005-03 |
|
| Treatment of cytomegalovirus infection or disease in solid organ transplant recipients with valganciclovir. | 2005-03 |
|
| Successful treatment of mediastinal lymphomatoid granulomatosis with rituximab monotherapy. | 2005-03 |
|
| Successful oral valganciclovir treatment of cytomegalovirus infection during Campath-1H therapy. | 2005-03 |
|
| [Valganciclovir maintenance therapy in AIDS: treatment failure due to the development of cytomegalovirus resistance to ganciclovir]. | 2005-02 |
|
| Molecular mechanisms of severe acute respiratory syndrome (SARS). | 2005-01-20 |
|
| Efficacy of valganciclovir administered as preemptive therapy for cytomegalovirus disease in liver transplant recipients: impact on viral load and late-onset cytomegalovirus disease. | 2005-01-15 |
|
| Kinetics of cytomegalovirus load decrease in solid-organ transplant recipients after preemptive therapy with valganciclovir. | 2005-01-01 |
|
| Antiviral therapy of congenital cytomegalovirus infection. | 2005-01 |
|
| Valganciclovir therapy for immune recovery uveitis complicated by macular edema. | 2005-01 |
|
| Pharmacokinetic profile of ganciclovir after its oral administration and from its prodrug, valganciclovir, in solid organ transplant recipients. | 2005 |
|
| Valganciclovir: a review of its use in the management of CMV infection and disease in immunocompromised patients. | 2005 |
|
| Similar reduction of cytomegalovirus DNA load by oral valganciclovir and intravenous ganciclovir on pre-emptive therapy after renal and renal-pancreas transplantation. | 2005 |
|
| Risk factors for cytomegalovirus viremia and disease developing after prophylaxis in high-risk solid-organ transplant recipients. | 2004-12-27 |
|
| Management of CMV infection and disease in transplant patients. 27-29 February 2004. | 2004-12 |
|
| Laboratory-based risk factors for cytomegalovirus retinitis. | 2004-12 |
|
| Cytomegalovirus prophylaxis using oral ganciclovir or valganciclovir in kidney and pancreas-kidney transplantation under antibody preconditioning. | 2004-12 |
|
| Cytomegalovirus retinitis in a patient treated with anti-tumor necrosis factor alpha antibody therapy for rheumatoid arthritis. | 2004-11-01 |
|
| Valgancyclovir as maintenance therapy for cytomegalovirus retinitis in a lung transplant patient--a case report. | 2004-11 |
|
| Pre-emptive treatment with oral valganciclovir in management of CMV infection after cardiac transplantation. | 2004-11 |
|
| Efficacy and safety of low-dose valganciclovir for prevention of cytomegalovirus disease in renal transplant recipients: a single-center, retrospective analysis. | 2004-10 |
|
| Cytomegalovirus ulcer. Successful treatment with valganciclovir. | 2004-10 |
|
| Following universal prophylaxis with intravenous ganciclovir and cytomegalovirus immune globulin, valganciclovir is safe and effective for prevention of CMV infection following lung transplantation. | 2004-10 |
|
| Valganciclovir prophylaxis in patients at high risk for the development of cytomegalovirus disease. | 2004-09 |
|
| Valganciclovir: oral prevention and treatment of cytomegalovirus in the immunocompromised host. | 2004-09 |
|
| Subretinal hemorrhage associated with cytomegalovirus retinitis in a patient without concurrent thrombocytopenia. | 2004-08 |
|
| Prevention and treatment of cytomegalovirus infection in solid organ transplant recipients. | 2004-08 |
|
| Cytomegalovirus prophylaxis with valganciclovir in kidney, pancreas-kidney, and pancreas transplantation. | 2004-08 |
|
| Treatment of cytomegalovirus disease with valganciclovir in renal transplant recipients: a single center experience. | 2004-07-27 |
|
| Transport of amino acid esters and the amino-acid-based prodrug valganciclovir by the amino acid transporter ATB(0,+). | 2004-07 |
|
| [Valganciclovir. Oral treatment of Cytomegalovirus infections]. | 2004-06-19 |
|
| Cytomegalovirus infection of the central nervous system. | 2004-06 |
|
| Valganciclovir for the prevention and treatment of cytomegalovirus disease in immunocompromised hosts. | 2004-02 |
|
| Lack of cytomegalovirus transmission after pancreatic islet transplantation. | 2004 |
|
| Viral prophylaxis in organ transplant patients. | 2004 |
|
| New AUC-based method to estimate drug fraction removed by hemodialysis. | 2004 |
|
| Kidney and pancreas transplantation at Wake Forest University Baptist Medical Center. | 2003 |
Patents
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:14:43 GMT 2025
by
admin
on
Mon Mar 31 18:14:43 GMT 2025
|
| Record UNII |
J0IEW0BSHV
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Preferred Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
DTXSID40170034
Created by
admin on Mon Mar 31 18:14:43 GMT 2025 , Edited by admin on Mon Mar 31 18:14:43 GMT 2025
|
PRIMARY | |||
|
135565147
Created by
admin on Mon Mar 31 18:14:43 GMT 2025 , Edited by admin on Mon Mar 31 18:14:43 GMT 2025
|
PRIMARY | |||
|
175865-61-9
Created by
admin on Mon Mar 31 18:14:43 GMT 2025 , Edited by admin on Mon Mar 31 18:14:43 GMT 2025
|
PRIMARY | |||
|
J0IEW0BSHV
Created by
admin on Mon Mar 31 18:14:43 GMT 2025 , Edited by admin on Mon Mar 31 18:14:43 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
PARENT -> SALT/SOLVATE |
